EDEN PRAIRIE, Minn., Feb. 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal first quarter ended December 31, 2024, before market open on February 12, 2025.
Management will host an investor conference call and webcast at 8:30 a.m. eastern time on Wednesday, February 12, 2025, to discuss the Company’s first quarter 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information:
First Quarter and Fiscal 2025 Earnings Conference Call
Date: Wednesday, February 12, 2025
Time: 8:30 a.m. Eastern time
U.S. Dial-In (Toll Free): 888-506-0062
International Dial-In: 973-528-0011
Participant Access Code: 234314
Webcast: https://www.webcaster4.com/Webcast/Page/2821/52002
Please join at least five minutes before the start of the call to ensure timely participation.
A playback of the call will be available through Wednesday, February 26, 2025. To listen, please call 877-481-4010 within the United States or 919-882-2331 when calling internationally, using replay passcode 51728. A webcast replay will also be available using the webcast link above through February 13, 2025.
About NeuroOne
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.
IR Contact
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.65 |
Daily Change: | 0.0076 1.19 |
Daily Volume: | 277,874 |
Market Cap: | US$19.890M |
April 23, 2025 March 05, 2025 February 12, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load